



RNS Number : 9862Y
Roquefort Therapeutics PLC
19 January 2022

19 January 2022

Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")

Director/PDMR Shareholding

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, advises that Stephen West, Executive Chairman has purchased ordinary shares in the Company in the market, as detailed below:

Name	Number of Ordinary Shares	Average Price Paid Per Share	Total Consideration Paid
Stephen West	150,000	10.36 pence	£15,542.10

Following the above purchase of shares, Mr West holds interests in the following Company securities:

Name	Number of Ordinary Shares Held	% of Issued Share Capital	Number of Warrants Held
Stephen West	4,550,000	6.33 %	7,500,000

4,399,000 of Mr West's shares are held in the name of Cresthaven Investments Pty Ltd ATF the Bellini Trust.

Enquiries:

Roquefort Therapeutics plc

Stephen West (Chairman) +44 (0)20 3290 9339

Buchanan (Public Relations)

Ben Romney / Jamie Hooper / George Beale +44 (0)20 7466 5000

Optiva Securities Limited (Broker)

Christian Dennis +44 (0)20 3411 1881

For further information on Roquefort Therapeutics, please visit www.roquefortinvest.com and @RoquefortTherap on Twitter.

LEI: 254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company's wholly owned subsidiary, Lynamid Pty Ltd ("LYRAMID"), is a pre-clinical biotech company focused on developing first in class Midkine inhibiting RNA therapeutics drugs for the treatment of cancer, chronic inflammatory, autoimmune disorder and COVID-19. Recent progress within mRNA therapeutics has led to a reduction in drug development timelines and costs, increasing the chance of early value creation.

Through extensive research resulting in validation through publication in over 1,000 scientific journals, Lynamid has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Lynamid holds the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). LYRAMID's pre-clinical programme is currently underway with an initial focus on cancer (including immunotherapy resistance) and COVID-19.

This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").

The notification below, made in accordance with the requirements of the UK MAR, provides further detail:

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1 Details of the person discharging managerial responsibilities / person closely associated

a) Name Stephen West

2 Reason for the notification

a) Position/status Executive Chairman

b) Initial notification /Amendment Initial

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name Roquefort Therapeutics plc
b) LEI 254900P4SISIWOR9RH34

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

- | | | | |
|----|---|---|-----------|
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.01 par value | |
| | Identification code | ISIN: GB00BMDQ2T15 | |
| b) | Nature of the transaction | Purchase of 150,000 ordinary shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | 10.31 pence per share | 100,000 |
| | | 10.46 pence per share | 50,000 |
| d | Aggregated information | | |
| | - Aggregated volume | - 150,000 | |
| | - Price | - 10.36p | |
| e) | Date of the transactions | 19 January 2022 | |
| f) | Place of the transactions | London Stock Exchange (XLON); Main Market | |

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBDGDBUUBDGDC

Anonymous (not verified)

Director/PDMR Shareholding

32402466

A

Wed, 01/19/2022 - 12:56

LSE RNS

Directors' Dealings

ROQ